Combinational Therapy of Capecitabine, Lapatinib and Vinorelbine for the Treatment of Patients With her2/Neu Positive, Relapsed or Metastatic Breast Carcinoma Following Treatment Failure With Trastuzumab.

Trial Profile

Combinational Therapy of Capecitabine, Lapatinib and Vinorelbine for the Treatment of Patients With her2/Neu Positive, Relapsed or Metastatic Breast Carcinoma Following Treatment Failure With Trastuzumab.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2015

At a glance

  • Drugs Lapatinib (Primary) ; Capecitabine; Vinorelbine
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CELAVIE
  • Most Recent Events

    • 20 Nov 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
    • 01 Apr 2014 Status changed from recruiting to suspended,as per European Clinical Trials Database record.
    • 14 Apr 2012 Planned number of patients changed from 36 to 84 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top